Racial Variation in the Cost-effectiveness of Chemotherapy for Prostate Cancer
May 18th 2011The likelihood of chemotherapy being cost-effective for patients with metastatic prostate cancer differs across racial subgroups. This uncertainty presents challenges for managed-care decision makers.
Read More
Effects of a Medicaid Prior Authorization Policy for Pregabalin
October 1st 2009State Medicaid programs’ pregabalin prior authorization accomplished the objective of lower pregabalin utilization; the unintended effects were increased opioid use and increased disease-related healthcare costs.
Read More